PART I Overview We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary ...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001493152-26-013612 | EDGAR | 101K words |
| 2025-03-27 | 2024-12-31 | 0001641172-25-000926 | EDGAR | — |
| 2024-03-18 | 2023-12-31 | 0001493152-24-010302 | EDGAR | — |
| 2023-03-20 | 2022-12-31 | 0001493152-23-008241 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001213900-22-011581 | EDGAR | — |
| 2021-03-10 | 2020-12-31 | 0001213900-21-014576 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001493152-25-021927 | EDGAR | 20K words |
| 2025-08-13 | 2025-06-30 | 0001641172-25-023471 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010547 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001493152-24-044010 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001493152-24-030766 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001493152-24-018422 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001493152-23-039896 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001493152-23-027345 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001493152-23-015940 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001493152-22-030819 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001493152-22-021610 | EDGAR | — |
| 2022-05-03 | 2022-03-31 | 0001213900-22-023583 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001493152-26-013608 | EDGAR | 5K words |
| 2026-01-23 | 0001493152-26-003314 | EDGAR | — |
| 2025-11-13 | 0001493152-25-022134 | EDGAR | — |
| 2025-09-23 | 0001493152-25-014652 | EDGAR | — |
| 2025-08-13 | 0001641172-25-023489 | EDGAR | — |
| 2025-07-29 | 0001641172-25-021407 | EDGAR | — |
| 2025-07-03 | 0001641172-25-017810 | EDGAR | — |
| 2025-05-15 | 0001641172-25-010541 | EDGAR | — |
| 2025-03-27 | 0001641172-25-000917 | EDGAR | — |
| 2025-01-10 | 0001493152-25-001685 | EDGAR | — |
85 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001763950 |
| Ticker | LTRN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | TX |
| Website | https://www.lanternpharma.com |
| Listed | 2020-06-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report